These findings suggest that treatments that either block Rab11a‐exosome biogenesis or suppress the active cargos on these exosomes might act synergistically with anti‐EGFR therapies to inhibit tumour growth and either slow or halt recurrence. This evidence concerns the gene RAB11A and neoplasm.